2. Signaling Pathways
  3. Immunology/Inflammation
  4. BCL6

BCL6

B-cell lymphoma 6 protein; B-cell lymphoma 5 protein (BCL-5); Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51

BCL6 (B-cell lymphoma 6) is a zinc-finger transcriptional repressor that plays a crucial role in the germinal center (GC) reaction of B cells. BCL6 can promote the continuous proliferation of B cells in the highly mutagenic GC environment by suppressing DNA damage checkpoint genes (ATR, CHEK1, TP53), thereby reducing the cellular response to DNA damage. Additionally, BCL6 facilitates B cell proliferation by downregulating cell cycle inhibitors (CDKN1A, PTEN) and prevents premature differentiation into plasma cells by repressing terminal differentiation genes (IRF4, PRDM1), ensuring the maintenance of the GC reaction. Furthermore, BCL6 competitively inhibits inflammatory signaling pathways (STAT3, NF-κB), thereby reducing excessive immune activation and exerting an anti-inflammatory effect.
The stable expression of BCL6 relies on positive feedback mechanisms, such as p300-mediated inhibition of HSP90 acetylation, which stabilizes BCL6, and EZH2-catalyzed H3K27 methylation, which further enhances BCL6's transcriptional repression. In various cancers, including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), chronic myeloid leukemia (CML), breast cancer, and non-small cell lung cancer (NSCLC), BCL6 contributes to cancer cell survival through genetic mutations, chromosomal translocations, or dysregulation of co-repressors. Therefore, inhibitors targeting the BTB domain of BCL6 can effectively block its interaction with co-repressors, thereby suppressing tumor growth and providing a novel therapeutic strategy for malignant tumors[1].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148631
    GSK137
    		Inhibitor
    GSK137 is an orally active, potent and selective B-cell lymphoma 6 (BCL6) inhibitor. GSK137 blocks the interaction between BCL6 and corepressors (e.g., SMRT), reducing the number of germinal center B cells. GSK137 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell-related tumors such as diffuse large B-cell lymphoma.
    GSK137
  • HY-177756
    BCL6-IN-11
    		Inhibitor
    BCL6-IN-11 (Compound 8) is an efficient inhibitor that induces partial degradation of BCL6 with its IC50 value for inhibiting the interaction between BCL6 and its co-inhibitory proteins (such as NCOR1) of 6 nM. BCL6-IN-11 can induce approximately 52% degradation of BCL6 after being treated with 5 μM concentration for 90 minutes, and thus is also classified as a partial degrader. BCL6-IN-11 can be used for the study of lymphoma.
    BCL6-IN-11
  • HY-169218
    WK692
    		Inhibitor
    WK692 is a BCL6 inhibitor that inhibits the BCL6BTB/SMRT interaction. WK692 can effectively inhibit the growth of diffuse large B-cell lymphoma cells and synergize with EZH2 and PRMT5 inhibitors..
    WK692
  • HY-164098
    JWZ-7-7-Neg1
    		Inhibitor
    JWZ-7-7-Neg1 is a transcriptional chemical inducers of proximity (TCIP) with negative chemical control. JWZ-7-7-Neg1 reduces the ability to bind to BRD4 or BCL6, so it has less cytotoxicity to DLBCL cells, in compared with JWZ-7-7.
    JWZ-7-7-Neg1
  • HY-178777
    BCL6-760
    		Degrader
    BCL6-760 is an orally active BCL-6 PROTAC degrader with an EC50 of 0.8 nM. BCL6-760 only degrades BCL6 and has no effect on other CRBN substrates. BCL6-760 demonstrates significant efficacy in the orthotopic xenograft mouse model of OCI-LY-1 tumors. BCL6-760 can be used in the research of diffuse Large B-cell Lymphoma (DLBCL) (Pink: BCL-6 ligand (HY-179317); Blue: CRBN ligand (HY-179305); Black: Linker).
    BCL6-760
  • HY-P10566
    BCOR(498-514), biotinylated
    		Inhibitor
    BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells.
    BCOR(498-514), biotinylated
  • HY-122829
    BCL6 PROTAC 1
    		Degrader
    BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC50 value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research.
    BCL6 PROTAC 1
  • HY-180166
    BCL6-IN-12
    		Inhibitor
    BCL6-IN-12 (Compound 11e) is a BCL6 inhibitor with a Kd of 0.81 μM. BCL6-IN-12 binds to the BTB domain of BCL6. BCL6-IN-12 can be used in the research of diffuse large B-cell lymphoma.
    BCL6-IN-12
  • HY-148640
    WK500B
    		Inhibitor
    WK500B is a potent and orally active BCL6 inhibitor with a KD of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL).
    WK500B
  • HY-179317
    BCL6 ligand-8
    		Degrader
    BCL6 ligand-8 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as BCL6-760 (HY-178777). BCL6-760 is a potent BCL6 PROTAC degrader with anti-tumor activity.
    BCL6 ligand-8
  • HY-177755
    BCL6-IN-10
    		Inhibitor
    BCL6-IN-10 (Compound 6) is a selective partially degradable molecular glue inhibitor that targets the BTB domain of BCL6 with an IC50 of 4 nM. BCL6-IN-10 shows anti-proliferative effect in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6-IN-10 can be used for the research of cancer .
    BCL6-IN-10
  • HY-176382
    BCL6 ligand-4
    BCL6 ligand-4 is an BCL6 ligand that can be used in the synthesis of PROTACs, such as BCL6 PROTAC 1 (HY-122829).
    BCL6 ligand-4
  • HY-172740
    BCL6 ligand-3
    		Inhibitor
    BCL6 ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). BCL6 ligand-3 can serve as an active control for the target protein ligand of BMS-986458 (HY-172736).
    BCL6 ligand-3
  • HY-173641
    MNN-02-155
    MNN-02-155 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. MNN-02-155 induces potent activation of the BCL6-target reporter gene and cell death. MNN-02-155 can be used for the study of diffuse large B cell lymphomas (DLBCLs).
    MNN-02-155
  • HY-P10543
    SMRT peptide
    		Inhibitor
    SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions.
    SMRT peptide
  • HY-178804
    BCL6 ligand-5
    		Ligand
    BCL6 ligand-5 (Compound 37) is a BCL6 ligand. BCL6 ligand-5 can be used as a ligand for target protein for PROTAC to develop and design degraders for PROTAC BCL6, such as PROTAC BCL6 Degrader-2 (HY-178803). BCL6 ligand-5 can also be used in tumor research.
    BCL6 ligand-5
  • HY-168907
    OICR11029
    OICR11029 is a highly efficient probe for Bcl-6.
    OICR11029
Cat. No. Product Name / Synonyms Application Reactivity